FDA-Drug2026-01-14Class IIPACKAGING DEFECT
Imprimis Tri-Moxi eye injection recalled for glass-like particles
What this means
Imprimis NJOF recalled Tri-Moxi+ eye injections because some batches contain glass-like particles. The affected batches (25JAN033A and 25JAN033B) expire in February 2026. No injuries have been reported.
- If you have Tri-Moxi+ (NDC 71384-746-06) with lot numbers 25JAN033A or 25JAN033B, do not use it.
- Contact your eye doctor or pharmacy immediately.
- Ask your healthcare provider about safe alternatives for your treatment.
The agency's original wording
Hazard
Presence of particulate matter - Glass like particles.
Intended for
Adults
Illnesses reported
None reported
Sold states
U.S Nationwide
Affected count
314 boxes of 6,280 pre-filled syringes
Manufactured in
1705 Route 46 Ste 6B, Ledgewood, NJ, United States
Products
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0251-2026Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.